Skip to main content
Active Surveillance Patients International

Understanding Your Prostate Biopsy Report: What Matters and What May Be Missing – with Dr. Jonathan Epstein

 

Understanding Your Prostate Biopsy Report: What Matters — and What May Be Missing

Understanding your prostate biopsy report is an important part of making decisions about prostate cancer, especially for men considering or living on Active Surveillance. Yet many of the terms used in biopsy reports can be confusing or unclear. Small differences in wording or interpretation can sometimes influence whether a patient stays on surveillance or moves toward treatment.

In this ASPI educational session, leading uropathologist, Dr. Jonathan Epstein, explains how prostate biopsy reports are interpreted in everyday clinical practice. The focus is on understanding what appears on your prostate biopsy report, which details truly matter, and which findings are often misunderstood or given more weight than they deserve.
 


 

How Prostate Biopsy Reports Are Interpreted

Prostate biopsy reports often include a mix of benign findings, borderline results, and cancer-related features. In this session, Dr. Epstein explains how pathologists examine biopsy tissue and how those findings are used to guide care decisions.

He reviews common terms such as inflammation, prostatic intraepithelial neoplasia (PIN), atypical intraductal proliferation (AIP), atypical small acinar proliferation (ASAP), intraductal carcinoma (IDC-P), Gleason patterns, Grade Groups, and cancer extent. Throughout the discussion, he emphasizes which findings usually affect risk assessment for men on Active Surveillance and which often do not.

The session also explains why biopsy grading can vary, how sampling limits accuracy, and when a second pathology opinion may be helpful.
 


 

Why Biopsy Interpretation Matters for Active Surveillance

For men on Active Surveillance, understanding your prostate biopsy report can ease uncertainty and support clearer conversations with your care team. This session explains why Grade Group is usually more important than cancer volume, why some biopsy terms sound more alarming than they are, and which findings deserve closer attention.

Dr. Epstein discusses intraductal carcinoma as an important exception that often changes management. He also explains how the percentage of Gleason pattern 4, cribriform growth, and grading accuracy can influence surveillance decisions. Additional topics include PSA changes over time, MRI-targeted biopsy, genomic testing, and how newer tools — including artificial intelligence — may shape future pathology review.

Key takeaways include:

  • Grade Group is usually more important than cancer volume when assessing risk
  • Inflammation, PIN, and many atypical findings often do not change management
  • Intraductal carcinoma requires careful review and often alters treatment plans
  • Expert pathology review can change interpretation in some cases
  • MRI-targeted biopsy improves detection but does not eliminate sampling limits

 


 

Watch the Discussion

Chapters

  • 00:00 – Welcome, ASPI disclaimers, and meeting introductions
  • 08:00 – What your prostate biopsy report can include
  • 08:44 – Benign tissue and inflammation: common misconceptions
  • 09:52 – PIN and AIP: meaning, follow-up, and reassurance
  • 14:40 – Intraductal carcinoma (IDC-P): why it changes management
  • 18:36 – ASAP and atypical findings in Active Surveillance
  • 22:45 – Prostate cancer grading: Gleason scores and Grade Groups
  • 32:17 – Is Gleason 6 really cancer?
  • 41:48 – Pattern 4, cancer volume, PSA, MRI, and AS decision factors
  • 54:04 – Genomic testing on Active Surveillance
  • 1:01:35 – AI in pathology: current role and limitations
  • 1:05:04 – Live Q&A with ASPI participants

 


 

About the Speaker

Dr. Jonathan Epstein is a widely respected uropathologist who specializes in diagnosing prostate cancer. He has played an important role in developing the Grade Group classification used today to assess prostate cancer risk.

Throughout his career, Dr. Epstein has helped define how prostate biopsy findings are interpreted, including atypical results and intraductal carcinoma. His work has been especially important for men on Active Surveillance, helping doctors better identify which cancers are low risk and which may need treatment.

Today, Dr. Epstein focuses on improving accuracy in prostate cancer diagnosis and supporting clear, patient-centered decision-making through education and consultation.
 


 

Learn More About Prostate Biopsy & Active Surveillance

Share this: